Market Trends of Italy In-Vitro Diagnostics Industry
Molecular Diagnostics Segment is Expected to Hold a Major Share in the Market Over the Forecast Period
Molecular diagnostics in in-vitro diagnostics offer several advantages, including high sensitivity, specificity, accuracy, and the ability to detect diseases early. They also provide faster results than traditional methods, critical for timely diagnosis and treatment. Additionally, molecular diagnostics enable targeted therapy and personalized medicine approaches, improving patient outcomes and reducing healthcare costs. Thus, due to the advantages mentioned above, molecular diagnostics is anticipated to have a higher adoption than the other techniques during the forecast period.
In addition, factors such as large outbreaks of bacterial and viral epidemics in Italy, increasing demand for point-of-care diagnostics, and rapidly evolving technology are also expected to impact the molecular diagnostics segment's growth significantly. For instance, according to an article published by the National Center for Biotechnology Information (NCBI) in December 2022, it was estimated that approximately 398,610 individuals in Italy were suffering from hepatitis C virus infection by January 2021. This significant patient population in Italy is fueling the demand and adoption of molecular diagnostic technologies for precise diagnosis and early screening and is subjected to segment growth.
Moreover, advancements in molecular diagnostics followed by new product launches and continuous engagement of the major players in the market are among the key factors expected to boost the segment's growth. For instance, in October 2021, ELITechGroup, an Italy-based company, launched the new CE-IVD stand-alone "Sample-to - Result" real-time (RT) PCR solution called ELITe BeGeniustoo. Similarly, in July 2021, DiaSorin S.p.A., an Italian manufacturer of diagnostics reagents and kits, acquired Luminex Corporation to broaden its position in the molecular diagnostics segment.
Thus, the benefits offered by molecular diagnostics, high disease prevalence, and strategic initiatives by the major players for increasing the availability of IVD instruments are expected to contribute to the segment's growth over the forecast period.
Instrument Segment is Anticipated to Have a Significant Share in the Market
In In-vitro diagnostics, instruments play a crucial role in the accurate and timely diagnosis of diseases and running various assays. These instruments are designed to perform multiple tasks, such as sample preparation, analysis, and result interpretation. They come in different types, including analyzers, spectrophotometers, chromatography systems, and mass spectrometers. Moreover, the instruments are one of the most essential components of any diagnostic center or clinic, so they are in huge demand.
Increasing initiatives by the Government and private organizations for investment in primary and community care are restructuring healthcare facilities and installation of advanced medical instruments. This is further increasing the demand for in-vitro diagnostic devices in Italy's healthcare settings and supporting the market's growth. For instance, according to an article by European Parliament in December 2021, it was stated that Italy's National Recovery and Resilience Plan includes the establishment of 380 new community hospitals and 1,350 new community health houses. Also, the plan consists of the structural upgradation of hospitals and purchasing of 3,133 state-of-the-art equipment items. Hence, establishing new centers and expanding existing ones are expected to drive the demand for in-vitro diagnostic instruments in Italy over the forecast period.
